BOONTON, N.J., Dec. 18, 2018 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, announced today that its Chief Executive Officer, Joel Tune, will present at Biotech Showcase 2019 to be held January 6-9, 2019, at the Hilton San Francisco Union Square.
Mr. Tune will present Enteris' corporate growth strategy and its focus on developing orally delivered peptide therapeutics for a broad range of treatment indications. Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence® platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class II, III and IV small molecules.
In 2018, Enteris announced positive results from the Phase 2a clinical trial of Ovarest®, an oral formulation of leuprolide, for the treatment of endometriosis. Data from the study indicated that Ovarest enabled significant suppression of estradiol (E2), demonstrating a measurable pharmacodynamic effect that is tightly correlated with efficacy in endometriosis.
Details of Enteris' presentation are as follows:
Biotech Showcase 2019
Tuesday, January 8, 2019
2:30 p.m. (Pacific Time)
Hilton San Francisco Union Square
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions utilizing its proprietary drug delivery technology, Peptelligence®. The technology has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma's most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed initially for the treatment of endometriosis, with possible follow on indications, including uterine fibroid tumors, prostate cancer, in vitro fertilization, and central precocious puberty. Tobrate® (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI). A third internal compound, octreotide, is currently in preclinical development. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit https://enterisbiopharma.com.
For Enteris BioPharma:
Brian Zietsman, President & CFO
Enteris Media Relations:
Tiberend Strategic Advisors, Inc.
SOURCE Enteris BioPharma, Inc.